View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


A New Medicaid Rebate Summit Announced for Early 2013

  • December 4, 2012

  • The Conference Forum, recognized in the pharmaceutical industry for its interactive-style meetings, is presenting a Medicaid Rebate Summit on February 14-15, 2013 in Washington, DC.  The Summit opens with Alice Valder Curran of Hogan Lovells on the anticipation of the Final Rule and is followed by an enforcement panel of US Attorney Offices.

    The Summit features Health Care Association insights on health care reform and POVs from Managed Markets, Government Contracting, Pricing and Reimbursement, States and Consultants. LaDonna Steiner of Purdue Pharma leads a Q&A with invited CMS representation. The event also features break-outs to cover Final Rule Implementation, 340B, Healthcare Exchanges, Medicaid Expansion and Medicare Part B&D.

    Speakers include representation from: Acorda Therapeutics, APEXUS/ 340B Prime Vendor Program, Bayer HealthCare LLC, BIO, Boehringer Ingelheim Pharmaceuticals, Inc., CIS, CMS, Daiichi Sankyo, District of Maryland, Eastern District of PA, Eli Lilly, Express Scripts, HP, Hogan Lovells, Genentech, Inc., HRSA Office of Pharmacy Affairs, Janssen, Janssen R&D, LLC, Mylan Pharmaceuticals, National Association of Chain Drug Stores, National Community Pharmacists Association, National Governors Association, PhRMA and Purdue Pharma.

    On February 13, there is an optional pre-conference workshop on the ABCs of Medicaid. The workshop is designed for professionals either new to the Medicaid Rebate space or for those looking for a refresher course on the basics.

    The Mission of the Summit is to address solutions for:

    1.  The interpretation of the Final Rule as best we know it

    2.  The larger implications of health care reform and its financial and operational impact on the expansion of the Medicaid Drug Rebates   program

    3.  A resolution to disputes and how to foster relationships between drug manufacturers and state agencies to better serve the Medicaid population